KAHR Bio has successfully secured $22 million in equity financing to advance the clinical development of its bispecific T-cell engager, DSP107, targeting MSS-CRC, with promising Phase 2a trial results indicating improved survival rates.

Information on the Target

KAHR Bio, a clinical-stage biotechnology firm based in Modiin, Israel, is advancing DSP107, an innovative bispecific 4-1BB-targeted T-cell engager. This cutting-edge therapy is currently under evaluation for its efficacy in treating advanced, chemo-refractory microsatellite stable colorectal cancer (MSS-CRC). Recently, the company announced promising topline results from its Phase 2a dose-expansion cohort, where DSP107 was tested alongside atezolizumab (Tecentriq®), an anti-PD-L1 therapy. Notably, the combination showed favorable safety and significant antitumor activity, particularly among patients with liver metastases.

Industry Overview in the Target’s Specific Country

The colorectal cancer market is substantial and represents one of the leading causes of cancer-related mortality globally. Within Israel, colorectal cancer has notably increased over recent years, paralleling global trends. As a result, there is a pressing demand for innovative therapies that can provide effective treatment options for patients suffering from advanced forms of the disease. The healthcare system actively supports research and development initiatives, particularly for oncology, positioning companies like KAHR Bio favorably within this landscape.

MSS-CRC is characterized by low tumor mutational burden and limited immune activation, leading to poor response rates with existing immunotherapies such as immune checkpoint